Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q1 2020 (← Previous) (Next →)

Filing Date: May 14, 2020

Total Value ($000): $241,630 (100.0% shares, 0.0% debt)

Holdings (16)

REPL Replimune Group 21.9%
Value ($000) $52,825 Shares 5,323,455 Est. Cost $17.40 Unrealized -14.3%
Morphic Holding 18.0%
Value ($000) $43,593 Shares 2,969,582 Est. Cost $19.82 Unrealized
GOSS Gossamer Bio 18.0%
Value ($000) $43,399 Shares 4,275,726 Est. Cost $20.85 Unrealized -37.4%
ARQT Arcutis Biothereapeutics 10.4%
Value ($000) $25,171 Shares 844,680 Est. Cost $26.87 Unrealized 0.0%
Translate Bio 10.1%
Value ($000) $24,303 Shares 2,437,603 Est. Cost $12.65 Unrealized
IMUX Immunic 3.4%
Value ($000) $8,298 Shares 1,371,494 Est. Cost $13.14 Unrealized -38.8%
Paratek Pharmaceuticals 3.4%
Value ($000) $8,191 Shares 2,600,410 Est. Cost $34.18 Unrealized
ESSA Pharma 2.8%
Value ($000) $6,759 Shares 1,689,848 Est. Cost $3.14 Unrealized
BEAM Beam Therapeutics 2.3%
Value ($000) $5,451 Shares 302,821 Est. Cost $21.73 Unrealized 0.0%
Cidara Therapeutics 2.1%
Value ($000) $4,980 Shares 2,008,150 Est. Cost $5.64 Unrealized
FibroGen 1.9%
Value ($000) $4,540 Shares 130,646 Est. Cost $27.34 Unrealized
TRVI Trevi Therapeutics 1.7%
Value ($000) $4,157 Shares 1,263,408 Est. Cost $8.61 Unrealized -47.0%
Prevail Therapeutics 1.4%
Value ($000) $3,326 Shares 272,807 Est. Cost $13.20 Unrealized
Jounce Therapeutics 1.0%
Value ($000) $2,517 Shares 529,965 Est. Cost $21.99 Unrealized
ObsEva 1.0%
Value ($000) $2,408 Shares 999,364 Est. Cost $9.76 Unrealized
Pieris Pharmaceuticals 0.7%
Value ($000) $1,712 Shares 750,741 Est. Cost $1.83 Unrealized